ARCHIMED has announced a definitive agreement to acquire Esperion Therapeutics, Inc. for up to $1.1 billion in equity value. The deal will pay Esperion shareholders $3.16 in cash per share at closing and grant them a non‑tradeable contingent value right (CVR) that could provide up to $100 million in milestone payments tied to future net sales. The transaction represents a 58% premium to Esperion’s closing share price on April 30, 2026, and is expected to close in the third quarter of 2026, subject to customary closing conditions and regulatory approvals.
Esperion’s recent financial performance has been a key driver of the premium. In the fourth quarter of 2025 the company reported a net income of $61.8 million and basic earnings per share of $0.26, a turnaround from prior losses. Full‑year 2025 results showed a net loss of $22.7 million, but revenue grew 144% year‑over‑year to $168.4 million, largely driven by the bempedoic acid franchise and partner revenues. The strong revenue growth offsets the company’s ongoing losses and stockholders’ deficit, positioning it as an attractive acquisition target.
The CVR structure is designed to align shareholder upside with Esperion’s commercial milestones. A $40 million tranche is tied to 2027 sales of Nexletol and Nexlizet exceeding $350 million, while a $60 million tranche is linked to Enbumyst revenues surpassing $160 million in any single year through 2030. These milestones reflect the company’s focus on expanding its cardiometabolic portfolio and leveraging its recent acquisition of Corstasis Therapeutics and its edema drug Enbumyst.
ARCHIMED’s strategy centers on investing in high‑growth, commercially mature biopharmaceuticals. By taking Esperion private, the deal removes the company from the public market, providing immediate liquidity for shareholders and allowing ARCHIMED to accelerate Esperion’s commercial platform. The acquisition also supports Esperion’s Vision 2040 strategy, which aims to broaden its product pipeline and deepen its presence in cardiometabolic and rare hepatic and renal conditions.
CEO Sheldon Koenig said, "This transaction marks an exciting new chapter for Esperion, our employees, and the patients and healthcare professionals we serve. ARCHIMED's acquisition of Esperion provides our shareholders with attractive and immediate upfront value at a compelling premium, while preserving the opportunity to participate in additional upside through contingent milestone payments tied to the future growth of our core cardiometabolic products." He added, "With ARCHIMED's support, we believe Esperion will be well positioned to advance our Vision 2040 strategy and continue addressing the global burden of cardiometabolic disease."
Following the announcement, analysts reviewed the transaction and adjusted their outlooks, reflecting the significant premium and the potential for milestone payments. The market reaction was strong, underscoring investor interest in the deal’s value proposition and the strategic fit between the two companies.
The acquisition will take Esperion private, ending its Nasdaq listing and providing shareholders with immediate liquidity. The combination of a substantial cash offer, a structured CVR, and ARCHIMED’s resources positions Esperion to scale its commercial operations and pursue its long‑term growth objectives under new ownership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.